<DOC>
	<DOCNO>NCT02624167</DOCNO>
	<brief_summary>A 4-week Phase IIa study evaluate safety tolerability efficacy NW-3509A patient chronic schizophrenia respond adequately current antipsychotic medication ( aripiprazole risperidone ) . NW-3509A give oral dose range 15 25 mg , BID 1:1 ratio .</brief_summary>
	<brief_title>A Study Determine Safety , Tolerability Efficacy NW-3509A Patients With Chronic Schizophrenia</brief_title>
	<detailed_description>This prospective , 4-week , randomize , double-blind , placebo-controlled , study design evaluate safety , tolerability , preliminary efficacy oral dose range NW-3509A 30 50 mg/day ( 15 25 mg , BID ) patient chronic schizophrenia stable dose antipsychotic ( aripiprazole risperidone ) . A minimum 90 patient randomize 1:1 ratio receive either NW-3509A ( n=45 ) placebo ( n=45 ) . Dose increase perform in-patient setting . Safety efficacy assessment do weekly basis randomize treatment period . The assessment safety base laboratory test ( biochemistry , hematology , urinalysis ) , 12-lead standard ECG , vital sign , physical examination , neurological examination , C-SSRS , ESRS-A , subjective reporting AE subject , objective observation AE Investigator . Pharmacokinetic sample take various time-points . Efficacy assessment include PANSS , CGI-C , CGI-S Strauss-Carpenter Level Functioning ( LOF ) scale .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Male/female ; female , must childbearing potential 2 . 18 65 year age , inclusive ; 3 . Has current diagnosis schizophrenia 4 . Has total score PANSS &lt; 75 . 5 . Positive symptom subscale score exceed 15 ; score â‰¥4 2 positive symptom 6 . Has Clinical Global Impression Severity disease ( CGIS ) rating mildly moderately severely ill. 7 . Is need antipsychotic treatment currently receive stable dose ( minimally 4 week prior screen oral risperidone aripiprazole ( least 2 mg risperidone doseequivalent ) . 8 . Current symptoms present least one month . 9 . Patient agree hospitalize 2 day start dose dose increase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>